New hope for tough prostate cancer: first human trial begins

NCT ID NCT06318273

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first study in people testing a new drug called ABBV-969 for men with advanced prostate cancer that has spread and no longer responds to standard hormone-blocking treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs it might help control the cancer. About 140 participants worldwide will receive the drug by IV infusion at different dose levels over up to three years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando /ID# 261686
RECRUITING

Orlando, Florida, 32803, United States
Ballarat Base Hospital /ID# 264294
RECRUITING

Ballarat, Victoria, 3350, Australia
Carolina BioOncology Institute /ID# 261602
RECRUITING

Huntersville, North Carolina, 28078, United States
Centre Hospitalier de l'Université de Montréal (CHUM) /ID# 270890
RECRUITING

Montreal, Quebec, H2X 0C1, Canada
Centre Leon Berard /ID# 270605
RECRUITING

Lyon, Rhone, 69373, France
Centre Oscar Lambret /ID# 270602
RECRUITING

Lille, Nord, 59000, France
Chris O'Brien Lifehouse /ID# 261731
RECRUITING

Camperdown, New South Wales, 2050, Australia
City of Hope /ID# 262059
RECRUITING

Duarte, California, 91010, United States
Hadassah Medical Center-Hebrew University /ID# 261771
RECRUITING

Jerusalem, 91120, Israel
Hospital Universitario HM Sanchinarro /ID# 271345
RECRUITING

Madrid, 28050, Spain
Hospital Universitario Vall de Hebron /ID# 270889
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocio /ID# 270617
RECRUITING

Seville, 41013, Spain
Institut Gustave Roussy /ID# 270603
RECRUITING

Villejuif, Île-de-France Region, 94800, France

Contact Phone: •••-•••-••••
Kyoto University Hospital /ID# 261861
RECRUITING

Kyoto, Kyoto, 606-8507, Japan
Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687
RECRUITING

Providence, Rhode Island, 02903-4923, United States
McGill University Health Centre - Glen Site. /ID# 271275
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
NEXT Oncology /ID# 261601
RECRUITING

San Antonio, Texas, 78229, United States
National Cancer Center Hospital /ID# 261698
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East /ID# 261606
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
Rambam Health Care Campus- Haifa /ID# 261770
RECRUITING

Haifa, 3525408, Israel
START Midwest /ID# 264295
RECRUITING

Grand Rapids, Michigan, 49546, United States
St Vincent's Hospital /ID# 264293
RECRUITING

Fitzroy, Victoria, 3065, Australia
The Chaim Sheba Medical Center /ID# 261772
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
Univ California, San Francisco /ID# 261715
RECRUITING

San Francisco, California, 94143-2204, United States
University of Chicago Medical Center /ID# 261605
RECRUITING

Chicago, Illinois, 60637, United States
Yale University School of Medicine /ID# 262234
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER